CTSD, CD63, MKD, NFKBIA, MAPK3, STAT3, TNFSF10, F2RL1, HIF1A, NEU1, and EPAS1 were identified as significantly expressed targets in patients with severe COVID-19 according to Aschenbrenner et al (Aschenbrenner et al., 2020). This evidence concerns the gene CD63 and COVID-19.